Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC AKC Refractory to Conventional Anti-Allergic Treatments
|
|
- Curtis Wells
- 5 years ago
- Views:
Transcription
1 Allergology International. ;6:75-8 DOI:. allergolint.-oa-65 ORIGINAL ARTICLE Usefulness of a New Therapy Using Rebamipide Eyedrops in Patients with VKC AKC Refractory to Conventional Anti-Allergic Treatments Mayumi Ueta,, Chie Sotozono, Ayaka Koga,, Norihiko Yokoi and Shigeru Kinoshita ABSTRACT Background: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflammation. In Japan, rebamipide eyedrops have recently been approved for the treatment of dry eye disease. Some patients with allergic conjunctival diseases such as vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) manifest dry eye with decreased tear break-up time only. We report patients with VKC AKC refractory to anti-allergic treatments who responded to the combination of rebamipide eyedrops and conventional anti-allergic treatments with anti-allergic- and or immunosuppressive steroid eyedrops. Methods: Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled rebamipide eyedrops three or four times a day for varying periods. All had dry eye with decreased tear break-up time. We evaluated changes in the size of their giant papillae using Image J software. Results: We observed attenuation of the giant papillae in all patients. In patients with severe disease, whose giant papillae had become larger despite the administration of tacrolimus and steroids, the addition of rebamipide contributed to their attenuation. In patients with mild disease, the giant papillae had become larger or remained the same size despite the administration of anti-allergy drugs; the addition of rebamipide eyedrops also resulted in the attenuation of their giant papillae. Conclusions: Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but also of allergic conjunctival diseases. KEY WORDS allergic conjunctivitis, atopy, dry eye with decreased tear break-up time, giant papilla, rebamipide INTRODUCTION Rebamipide eyedrops have been approved in Japan for the treatment of dry eye disease. They up-regulate the production and secretion of mucin. Kinoshita et al., reported that the administration of was well-tolerated and effectively improved objective signs and the subjective symptoms of dry eye. Rebamipide, a gastroprotective drug, increases gastric mucus production,5 and suppresses gastric mucosal inflammation 6,7 Naito et al. 8 reported that rebamipide was dominantly distributed in mucosal tissues. Elsewhere we showed that it suppressed polyi: C-induced inflammatory cytokines in human conjunctival epithelial cells 9 and Kimura et al. documented that rebamipide protects corneal epithelial cells from the TNFα-induced disruption of barrier function by maintaining the distribution and expression of ZO- as well as the organization of the actin cytoskeleton. Department of Ophthalmology, Kyoto Prefectural University of Medicine and Faculty of Life and Medical Sciences, Doshisha University, Kyoto, Japan. Authors Contributions: MU, CS, AK, NY, and SK contributed materials for the research. MU wrote the manuscript and reviewed it. All the authors approved the final manuscript. Conflict of interest: SK received research funding from Otsuka Pharmaceutical. The rest of the authors have no conflict of interest. Correspondence: Mayumi Ueta, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Hirokoji, Kawaramachi, Kamigyo-ku, Kyoto 6 8, Japan. mueta@koto.kpu m.ac.jp Received 9 July. Accepted for publication 9 September. Japanese Society of Allergology Allergology International Vol 6, No, 75
2 Ueta M et al. It also suppressed the TNFα-induced expression of interleukin-6 and interleukin-8 at the mrna- and protein level and inhibited the TNFα-induced degradation of IκBα. Some patients with allergic conjunctival diseases manifest dry eye with only decreased tear break-up time (BUT)., We prescribed rebamipide eyedrops to patients with allergic conjunctival diseases with giant papillae who presented with dry eye. We now report patients with VKC AKC refractory to conventional treatment with anti-allergic- and or immunosuppressive steroid eyedrops who responded to the combination of rebamipide eyedrops and conventional anti-allergic treatments. METHODS This study was a case report on the VKC AKC patients with giant papillae intractable for a conventional anti-allergic treatment undergoing topical combined therapy using rebamipide eyedrops. Our study included patients with allergic conjunctival diseases with giant papillae (VKC or AKC) and dry eye with decreased tear break-up time, which we treated with rebamipide in. They were males and females; their age ranged from - 8 years (mean 9.5). They were instructed to instill rebamipide eyedrops three or four times a day for varying periods. We started the administration of rebamipide eyedrops when the patients have dry eyes, and the size of giant papillae had increased despite the more than -week administration of tacrolimus and steroids (severe cases), or had become larger or remained the same despite the use of anti-allergy drugs (mild cases). We observed attenuation of the giant papillae in all patients with VKC or AKC. We evalutated changes in the size of their giant papillae and in the area of involvement. The study protocol was approved by the ethical review board of Kyoto Prefectural University of Medicine; all patients provided writteninformedconsent. We marked the papillae on photographs of the ocular surface and calculated their size using Image J software (Fig. ). We show their total- and average size. Data were expressed as the mean ± SE and evaluated by Student s t-test using Microsoft Excel software. RESULTS CASE 7-year-old man with left AKC. He previously had undergone penetrating keratoplasty for limbal stem cell deficiency. He was on topical tacrolimus (.%, day), fluorometholone (. day), and systemic prednisolone ( mg day) for more than a year before starting therapy with rebamipide eyedrops. We prescribed rebamipide eyedrops to him when the size of his giant papillae and the area of involvement continued to increase; his left BUT was sec at that time. Fig. We measured the size of the giant papillae on photographs of the ocular surface obtained before and at the indicated times during rebamipide treatment using Image J software. Two weeks of rebamipide treatment yielded no attenuation although the discharge and itching were reduced. After 6 weeks the giant papillae were smaller and his subjective symptoms were milder and the prednisolone dose was reduced to 5 mg day. After weeks of rebamipide therapy his papillae were almost flat. Prednisolone was stopped 7 weeks after the start of rebamipide administration and at the last follow-up, performed about one year later, his giant papillae were silent (data not shown). Figure shows the pictures of his left upper eyelid, drug history and graphs showing the size of total- and the each area of 76 Allergology International Vol 6, No,
3 New Therapy Using Rebamipide for VKC AKC w 6 w w.% tacrolimus &.% fluorometholone prednisolone ( mg/ day) (systemic).5% moxifloxacin & clarithromycin ( mg/ day) (systemic) prednisolone (5 mg/ day) (systemic) Total area of giant papillas 6 5 Each area of giant papillas * 8 6 w 6 w w 6 w Fig. Case - A patient with atopic keratoconjunctivitis. The size of total- and each area of the giant papillae at -, -, and 6 weeks after starting rebamipide treatment are shown. Data are expressed as the mean ± SE and evaluated by Student s t-test using Microsoft Excel software (*p <.5). the giant papillae at -, -, and 6 weeks after starting rebamipide treatment. CASE -year-old boy with right VKC. The topical administration of tacrolimus (.%, day) and betamethasone (.%, day) had been ineffective and he suffered severe VKC with massive superficial punctate keratopath and visual impairment. Therefore, we added systemically prednisolone ( mg day) for weeks and then replaced betamethasone with fluorometholone (.%, day for weeks). However, despite these treatments his VKC again became severe and rebamipide therapy was started; his right BUT was sec at that time. After weeks his giant papillae were smaller and the severity of his symptoms was decreased. After 6 weeks the giant papillae were almost flat; their flattening continued until week Allergology International Vol 6, No, 77
4 Ueta M et al. (/day).% tacrolimus.% fluorometholone w 6 w.% gatifloxacin w.% fluorometholone Total area of giant papillas Each area of giant papillas *** *** w 6 w w 6 w Fig. Case - A patient with vernal conjunctivitis. The size of total- and each area of the giant papillae at -, -, and 6 weeks after starting rebamipide treatment are shown. Data are expressed as the mean ± SE and evaluated by Student s t-test using Microsoft Excel software (***p <.5).. Figure shows the pictures of his left upper eyelid, drug history and graphs showing the size of totaland the each area of the giant papillae at -, -, and 6 weeks after the start of rebamipide instillation. CASE When we first saw this -year-old girl with VKC she was on topical fluorometholone (.%, day) and olopatadine (.%, day). We added rebamipide eyedrops ( day); her right BUT was sec at that time. Although she arbitrarily stopped fluorometholone instillation after one week, after weeks of rebamipide treatment her giant papillae became smaller and the severity of discharge and itching was lessened. After 78 Allergology International Vol 6, No,
5 New Therapy Using Rebamipide for VKC AKC.% fluorometholone- w.% olopatadine w Total area of giant papillas Each area of giant papillas 7 6 ** w w w w Fig. Case - A patient with vernal conjunctivitis. The size of total- and each area of the giant papillae at -, -, and weeks after starting rebamipide treatment are shown. Data are expressed as the mean ± SE and evaluated by Student s t-test using Microsoft Excel software (**p <.). weeks her giant papillae were yet smaller and flatter. She subsequently was treated elsewhere. Figure shows the pictures of his left upper eyelid, drug history and graphs showing the size of total- and the each area of her giant papillae at -, -, and weeks after the start of rebamipide therapy. CASE This 8-year-old man presented with bilateral AKC. He had suffered several episodes of herpetic keratitis in the right or left eye. He was treated with olopatadine (.%, day) without topical steroids to prevent the recurrence of herpetic keratitis. Rebamipide treatment was added when his giant papillae became bigger and the area of involvement increased; his right and left BUT was sec at that time. After 6 weeks his discharge and itching were reduced and his giant papillae were smaller as was the area of involvement. Figure 5 shows the pictures of his both upper eyelid, drug history and graphs showing the size of total- and Allergology International Vol 6, No, 79
6 Ueta M et al. right left (/day).% olopatadine &.% sodium- 6 w hyaluro- nate 5 right Total area of papillas 8 left Total area of papillas w right Each area of papillas.5 6 w left Each area of papillas ** 6 w P =.8 6 w Fig. 5 Case - A patient with atopic keratoconjunctivitis. The size of total- and each area of the giant papillae at - and 6 weeks after starting rebamipide treatment are shown. Data are expressed as the mean ± SE and evaluated by Student s t-test using Microsoft Excel software (**p <.). the each area of the giant papillae at - and 6 weeks after the start of rebamipide treatment. DISCUSSION Our findings suggest that rebamipide eyedrops might contribute to the reduction of giant papillae in patients with AKC and VKC. Rebamipide has been used to treat gastritis and gastric ulcers; it suppresses gastric mucosal inflammation,5 and increases gastric mucus production., We posited that rebamipide eyedrops may also exert anti-inflammatory effects on the ocular surface. Elsewhere we reported that rebamipide suppressed the polyi: C-induced production of CXCL, CXCL, RANTES, MCP-, and IL-6 in human conjunctival epithelial cells, and that its topical administration sup- 8 Allergology International Vol 6, No,
7 New Therapy Using Rebamipide for VKC AKC pressed conjunctival allergic eosinophil infiltration in our murine allergic conjunctivitis model. 6 Others found that rebamipide protects corneal epithelial cells from the TNFα-induced disruption of barrier function andthatitsuppressedthetnfα-induced expression of interleukin-6 and interleukin-8 at the mrna- and protein level. 7 We administered rebamipide eyedrops to patients with allergic conjunctival diseases with giant papillae and found that it helped to decrease their size and area of involvement. In two patients (cases and ) whose giant papillae worsened despite the administration of immunosuppressants and steroids, the addition of rebamipide eye drops exerted antiinflammatory effects. In the other patients with less severe disease (cases and ), the administration of rebamipide eyedrops with anti-allergy drugs also produced anti-inflammatory effects. Based on our observations we suggest that the anti-inflammatory effects of rebamipide eyedrops may help to combat human ocular surface inflammation. On the other hand, in a patient with giant papillary conjunctivitis induced by soft contact lenses, the administration of rebamipide eyedrops failed to reduce the size of the giant papillae (data not shown). Therefore, we think that rebamipide might not be effective in patients with giant papillary conjunctivitis. On the other hand, we also encountered a patient whose giant papillae became smaller and the discharge and itching were alleviated by the sole treatment with rebamipide eyedrops (Supplementary Fig. ). This suggests that even the sole administration of rebamipide eyedrops may reduce mild giant papillae. To confirm the effectiveness of rebamipide eyedrops in the treatment of various allergic conjunctival diseases, more investigations are needed. In conclusion, our experience suggests that the combination of rebamipide eyedrops and conventional anti-allergic treatments with anti-allergic- and or immunosuppressive steroid eyedrops may represent a new effective therapy for VKC AKC refractory to the usual anti-allergic treatments and that rebamipide eyedrops-may also be effective in the treatment of not only dry eye but also allergic conjunctival diseases. ACKNOWLEDGEMENTS This work was supported in part by grants-in-aid for scientific research from the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Culture, Sports, Science and Technology, a research grant from the Kyoto Foundation for the Promotion of Medical Science, and the Intramural Research Fund of Kyoto Prefectural University of Medicine. SUPPLEMENTARY MATERIALS Supplementary Figure is available online. REFERENCES. Urashima H, Takeji Y, Okamoto T, Fujisawa S, Shinohara H. Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cell density in normal rabbits. JOculPharmacolTher;8:6-7.. Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide (OPC-759) in the treatment of dry eye: A randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology ;9:7-8.. Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N. A randomized, multicenter phase study comparing (OPC-759) with.% sodium hyaluronate in the treatment of dry eye. Ophthalmology ;: Iijima K, Ichikawa T, Okada S et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: Evaluations with endoscopic gastrin test. Dig Dis Sci 9;5: Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 99;: Murakami K, Okajima K, Uchiba M et al. Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 997;: Yoshida N, Yoshikawa T, Iinuma S et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 996;: Naito Y, Yoshikawa T, Iinuma S et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittelforschung 996;6: Ueta M, Sotozono C, Yokoi N, Kinoshita S. Rebamipide suppresses PolyI: C-stimulated cytokine production in human conjunctival epithelial cells. JOculPharmacolTher ;9: KimuraK,MoritaY,OritaT,HarutaJ,TakejiY,Sonoda KH. Protection of human corneal epithelial cells from TNF-alpha-induced disruption of barrier function by rebamipide. Invest Ophthalmol Vis Sci ;5: Tanaka H, Fukuda K, Ishida W, Harada Y, Sumi T, Fukushima A. Rebamipide increases barrier function and attenuates TNF alpha-induced barrier disruption and cytokine expression in human corneal epithelial cells. British J Ophthalmol ;97:9-6.. Suzuki S, Goto E, Dogru M et al. Tear film lipid layer alterations in allergic conjunctivitis. Cornea 6;5: Toda I, Shimazaki J, Tsubota K. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology 995;:-9. Allergology International Vol 6, No, 8
Dr.Sushil Kumar Tripathi
Rabamipide:360 Benefits in Dry eye syndrome Dr.Sushil Kumar Tripathi Prevalence of Dry Eye Syndrome: vone in four patients attending ophthalmic clinics report symptoms of dry eye. vprevalence of dry eye
More informationProvided as a service by CiplaMed
Allergy Reaction of the body tissues to an allergen which leads to production of antibodies finally culminating in an antigen-antibody antibody reaction. Normal Individual Entry of allergen Allergen-Antibody
More informationCombined Medical and Surgical Treatment of Severe Vernal Keratoconjunctivitis
CLINICAL INVESTIGATIONS Combined Medical and Surgical Treatment of Severe Vernal Keratoconjunctivitis Hiroshi Fujishima,*, Kazumi Fukagawa,* Yoshiyuki Satake,* Ichiro Saito, Jun Shimazaki,* Yoji Takano*,
More informationTherapeutic Effects of 0.1% Tacrolimus Eye Drops for Refractory Vernal Keratoconjunctivitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 3 Ver. VI (Mar. 2016), PP 44-48 www.iosrjournals.org Therapeutic Effects of 0.1% Tacrolimus
More informationOcular Surface Disease in Atopic Dermatitis
Ocular Surface Disease in Atopic Dermatitis Murat Dogru,* Naoyuki Nakagawa, Kazuaki Tetsumoto, Chikako Katakami* and Misao Yamamoto* *Department of Ophthalmology, Kobe University School of Medicine, Kobe,
More informationPokharel S 1, Shah DN 2, Choudhary M 3 1 Lecturer Ophthalmology Department, KMC, Sinamangal, 2 Professor and 3 Lecturer, Ophthalmology Department,
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 526-530 Original Article Vernal keratoconjunctivitis: Modes of presentation in Nepalese population Pokharel S 1, Shah DN 2, Choudhary
More informationGenetic susceptibility for Stevens-Johnson syndrome/toxic epidermal necrolysis with mucosal involvements
249 Special Issue: Inflammation in Ophthalmology Review Article Genetic susceptibility for Stevens-Johnson syndrome/toxic epidermal necrolysis with mucosal involvements 1, 2, ) Mayumi Ueta 1) Department
More informationDr Rachael Neiderer. Ophthalmologist Auckland. 8:35-8:50 Managing Allergic Conjunctivitis & Why Sodium Chromoglycate is Out
Dr Rachael Neiderer Ophthalmologist Auckland 8:35-8:50 Managing Allergic Conjunctivitis & Why Sodium Chromoglycate is Out Allergic conjunctivitis Rachael Niederer Greenlane Clinical Centre, Auckland Case
More informationOcular allergy pathogenesis and diagnosis
Ocular allergy pathogenesis and diagnosis Luís Delgado, MD PhD departament of Immunology and Immunoallergology Unit Hospital de S. Joao. Porto (Portugal) Marzo 2006 www.alergomurcia.com Good morning, Mr.
More informationOcular Allergy. Phil Lieberman, MD
Ocular Allergy Phil Lieberman, MD Disclosure Consultant/Advisory Board: Genentech, Meda, Mylan, Teva Speaker: Genentech, Meda, Merck, Mylan, Teva Learning Objectives Upon completion of this session, participants
More informationDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan
Ophthalmology Volume 2016, Article ID 3573142, 5 pages http://dx.doi.org/10.1155/2016/3573142 Clinical Study Clinical Usefulness of Monitoring Expression Levels of CCL24 (Eotaxin-2) mrna on the Ocular
More information12/3/2011. Disclosure. Allergic Eye Disease: Diagnostic Pearls and Treatment Options. Symptoms. Allergy Eye Disease
Disclosure Allergic Eye Disease: Diagnostic Pearls and Treatment Options I have no financial relationships to disclose. Ophthalmology Update 2011 Matilda Chan MD, PhD Department of Ophthalmology, UCSF
More informationOcular Allergies: Scratching the Surface. -20%-50% of the population has allergies -83% of allergy sufferers experience ocular symptoms
How Many People Are Affected? Ocular Allergies: Scratching the Surface Mile Brujic, OD -20%-50% of the population has allergies -83% of allergy sufferers experience ocular symptoms Disclosure: I have no
More informationSubject Index. Atopic keratoconjunctivitis (AKC) management 16 overview 15
Subject Index Acanthamoeba keratitis, see Infective keratitis Acute allergic conjunctivitis AKC, see Atopic keratoconjunctivitis Allergy acute allergic conjunctivitis 15 atopic keratoconjunctivitis 15
More informationChildhood corneal neovascularization
Miltos Balidis PhD, FEBOphth, ICOphth Sotiria Palioura MD,PhD Childhood corneal neovascularization Opacities Cornea clarity is essential for optimal vision at any age. In childhood, loss of corneal transparency
More informationItchy eyes a little irritation or a big pain
Itchy eyes a little irritation or a big pain Mrs Melanie Hingorani Consultant Ophthalmologist Moorfields Eye Hospital Declaration of any conflicts of interest None Allergic Eye Disease Group of disorders
More informationLong-term results of autologous cultivated oral mucosal epithelial transplantation in the scar phase of severe ocular surface disorders
1 Department of Ophthalmology, Kyoto Prefectural University of Medicine, Graduate School of Medicine, Kyoto, Japan 2 Research Center for Inflammation and Regenerative Medicine, Doshisha University, Kyoto,
More informationShizuka Koh, M.D. Ph. D.
CURRICULUM VITAE Page 1 CURRICULUM VITAE Shizuka Koh, M.D. Ph. D. Shizuka Koh, M.D. Ph. D. Department of Ophthalmology University of Rochester 247 Meliora Hall Rochester, NY 14627 Phone : 585-275-8675
More informationEffectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
Ueda et al. BMC Ophthalmology (2015) 15:58 DOI 10.1186/s12886-015-0040-0 RESEARCH ARTICLE Open Access Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye Kaori
More informationOCULAR ALLERGY IN CHILDREN. Presenter: Dr C.L.A Ogundo Consultant Ophthalmologist KPA conference April 2017
OCULAR ALLERGY IN CHILDREN Presenter: Dr C.L.A Ogundo Consultant Ophthalmologist KPA conference April 2017 Introduction Hypersensitivity disorder Conjunctival surface is accessible to allergens and is
More informationDefinition. Acute inflammation of the conjunctiva due to either viral or bacterial infection
療 Acute Conjuctivitis Definition Acute inflammation of the conjunctiva due to either viral or bacterial infection Viral causes Causes include adenovirus, Herpes simplex. Bacterial causes include Streptococcus
More informationPAINFUL PAINLESS Contact lens user BOV
Common Causes Allergies Infections Ocular Cornea, uveitis, endophthalmitis Orbital Orbital cellulitis Inflammation Uveitis Scleritis / episcleritis Glaucomas Trauma Foreign bodies Chemical injuries History
More informationTacrolimus Ointment for Treatment of Vernal keratoconjunctivitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 3 Ver. VI (March. 2017), PP 29-37 www.iosrjournals.org Tacrolimus Ointment for Treatment of
More informationOphthalmic Antihistamine Step Therapy Program Summary
Ophthalmic Antihistamine Step Therapy Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-8 Drug FDA Indication(s) Administration and Dosing Bepreve Treatment of itching associated Instill one drop into
More informationScreening of dry eye disease in visual display terminal workers during occupational health examinations: The Moriguchi study
Motoko KAWASHIMA, et al.: Screening of dry eye in visual display terminal workers J Occup Health 2015; 57: 253 258 253 Journal of Occupational Health Screening of dry eye disease in visual display terminal
More informationEfficacy of Tear Eosinophil Cationic Protein Level Measurement Using Filter Paper for Diagnosing Allergic Conjunctival Disorders
Efficacy of Tear Eosinophil Cationic Protein Level Measurement Using Filter Paper for Diagnosing Allergic Conjunctival Disorders Jun Shoji*, Minoru Kitazawa*, Noriko Inada*, Mitsuru Sawa*, Tetsuya Ono,
More informationEffect of Topical Cyclosporine 0.05% in Allergic Conjunctivitis
Effect of Topical Cyclosporine 0.05% in Allergic Conjunctivitis Delhi J Ophthalmol 2015; 25 (3): 171-175 DOI: http://dx.doi.org/10.7869/djo.101 * Sonali Bhalla, SK Sachan **, AM Jain ** * Bhalla Medical
More informationSUBMISSION FOR RECLASSIFICATION OF MEDICINE. ZADITEN (KETOTIFEN 0.025% for Ophthalmic Use) TT , TT /1
SUBMISSION FOR RECLASSIFICATION OF MEDICINE ZADITEN (KETOTIFEN 0.025% for Ophthalmic Use) TT50-7009, TT50-7009/1 June 2008 PART A 1. International non-proprietary name Ketotifen 2. Proprietary name Zaditen
More informationCondition: Allergic Eye Disease (Type 1 Hypersensitivity reactions)
Condition: Allergic Eye Disease (Type 1 Hypersensitivity reactions) Description: Seasonal allergic conjunctivitis is caused by seasonal allergens, especially grass pollen, whereas perennial conjunctivitis
More informationConjunctivitis in Cats
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Conjunctivitis in Cats (Inflammation of the Moist Tissues of the Eye) Basics OVERVIEW
More informationOCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY
OCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY SURFACE DISEASE DRY EYE DYSFUNCTIONAL TEARS SYND ALLERGIC DISORDERS MEIBOMIAN GLAND PROBLEMS OCULAR IMMUNE
More informationH erpes simplex virus infection of the
Herpes simplex keratitis An experimental study Samuel J. Kimura, Victor Diaz-Bonnet, and Masao Okumoto The incidence of complicated herpes simplex keratitis appears to have increased and the important
More informationPage 1 RED EYES. conjunctivitis keratitis episcleritis / scleritis. Frank Larkin Moorfields Eye Hospital. acute glaucoma anterior uveitis
The RED EYE and ALLERGIC EYE DISEASE DIAGNOSIS & MANAGEMENT Frank Larkin Moorfields Eye Hospital RED EYES conjunctivitis keratitis episcleritis / scleritis acute glaucoma anterior uveitis post-op. / trauma
More informationGrow Your Practice With a Focus on Ocular Allergy
By Scot Morris, O.D., F.A.A.O. Grow Your Practice With a Focus on Ocular Allergy Build your allergy patient base by making accurate diagnoses, offering the best treatments and increasing revenues with
More informationThe Red Eye: Conjunctivitis, Iritis, or Worse? Sean P. Donahue, MD, PhD
The Red Eye: Conjunctivitis, Iritis, or Worse? Sean P. Donahue, MD, PhD Sam and Darthea Coleman Chair Vice Chair of Clinical Affairs, Department of Ophthalmology Professor of Pediatrics, Ophthalmology,
More informationulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236
Subject Index Actin cellular forms 48, 49 epidermal growth factor, cytoskeletal change induction in mucosal repair 22, 23 wound repair 64, 65 polyamine effects on cytoskeleton 49 51 S-Adenosylmethionine
More informationProceedings of the Southern European Veterinary Conference and Congreso Nacional de AVEPA
www.ivis.org Proceedings of the Southern European Veterinary Conference and Congreso Nacional de AVEPA Oct. 18-21, 2012 - Barcelona, Spain Next Conference: Oct. 17-19, 2013 - Barcelona, Spain Reprinted
More informationStatus of Clinical Development
Status of Clinical Development May 10, 2005 Toshiaki Nishihata, Ph.D. Senior Corporate Officer Head of Research and Development Division 1 Progress of the Medium-term Management Plan - In the last fiscal
More informationDry Eye Assessment and Management Study ELIGIBILITY OCULAR EVALUATION FORM
Page 1 of 13 BEFORE COMPLETING THE OCULAR EXAMINATION, YOU MUST BE ABLE TO ANSWER YES TO THE FOLLOWING QUESTIONS: Have you done MMP9? (SVonly) The Following are done at Baseline: Have you done Tear Osmolarity?
More informationNew Ways to Ease Allergy Symptoms
New Ways to Ease Allergy Symptoms New pharmacologic and immunotherapeutic agents may offer options for allergy sufferers. Michelle Stephenson, Contributing Editor 3/8/2012 Allergy season is quickly approaching,
More informationfounder of McDonald s Restaurants
Press On Nothing in the world can take the place of persistence. Talent will not; nothing is more common than unsuccessful men with talent. Genius will not; unrewarded genius is almost a proverb. Education
More informationJMSCR Vol 05 Issue 01 Page January 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i1.86 Study of Clinical Features and Management
More informationBreaking the Cycle. Yijie (Brittany) Lin, MD, MBA, Reena Garg, MD New York Eye and Ear Infirmary of Mount Sinai
Lin, Garg Ophthalmology Times 1 Breaking the Cycle Yijie (Brittany) Lin, MD, MBA, Reena Garg, MD New York Eye and Ear Infirmary of Mount Sinai Abstract A 32 year-old female with a history of LASIK surgery
More informationOcular allergy: implications for the clinical immunologist C. H. Katelaris, MD, PhD
Ocular allergy: implications for the clinical immunologist C. H. Katelaris, MD, PhD Background: Allergic diseases of the eye are the most common conditions affecting the external ocular adnexa. The most
More informationORIGINAL ARTICLE INTRODUCTION
Allergology International. ;:- ORIGINAL ARTICLE Efficacy of Hydrochloride Ophthalmic Suspension in the Conjunctival Allergen Challenge Test in Japanese Subjects with Seasonal Allergic Conjunctivitis Etsuko
More informationOphthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,4 Agent Indication Dosage and Administration Restasis (cyclosporine ophthalmic emulsion)
More informationTacrolimus versus Cyclosporine- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis
Original Article Kumari R et al DOI: http://dx.doi.org/10.3126/nepjoph.v9i2.19257 e- Comparative Evaluation as First line drug in Vernal keratoconjuctivitis Rashmi Kumari 1, Bhawesh Chandra Saha 2, Bibhuti
More informationAllergic manifestations of contact lens wearing
REVIEW C URRENT OPINION Allergic manifestations of contact lens wearing Abraham Solomon Purpose of review Contact lens-induced papillary conjunctivitis (CLPC) is a common ocular allergic disease in contact
More informationPeople with eye allergies typically have symptoms that include: Eye Anatomy: What Do Eye Allergies Actually Effect?
Eye Allergies Eye Allergies People with eye allergies typically have symptoms that include: Itchy watery eyes Eyelid problems Dark circles around eyes Dry eyes Reactions to Contacts Let us help allow you
More informationEfficacy and Safety of Diquafosol Ophthalmic Solution in Patients with Dry Eye Syndrome: A Japanese Phase 2 Clinical Trial
Efficacy and Safety of Ophthalmic Solution in Patients with Dry Eye Syndrome: A Japanese Phase 2 Clinical Trial Yukihiro Matsumoto, MD, 1 Yuichi Ohashi, MD, 2 Hitoshi Watanabe, MD, 3 Kazuo Tsubota, MD,
More informationSECOND SEASON PREDNISONE TREATMENT IN VERNAL CONJUNCTIVITIS WITH SPECIAL REFERENCE TO CORNEAL COMPLICATIONS*
Brit. J. Ophthal. (1958) 42, 674. SECOND SEASON PREDNISONE TREATMENT IN VERNAL CONJUNCTIVITIS WITH SPECIAL REFERENCE TO CORNEAL COMPLICATIONS* BY ELI NEUMANN From the Department of Ophthalmology, Hadassah
More informationThe first comprehensive definition of DED was published in
Special Issue Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions Jun Shimazaki Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital,
More informationDo You Want Steroids with THAT?! Bruce Onofrey, OD, RPh, FAAO
Do You Want Steroids with THAT?! Bruce Onofrey, OD, RPh, FAAO Disclosure Statement: Nothing to disclose Please remember to complete your session evaluations on the Academy.18 meeting app Tweet about this
More informationHuman adenoviral type 54 keratoconjunctivitis accompanied by stellate keratitis and keratic precipitates: two cases
Matsuura et al. BMC Ophthalmology (2019) 19:7 https://doi.org/10.1186/s12886-018-1025-6 CASE REPORT Open Access Human adenoviral type 54 keratoconjunctivitis accompanied by stellate keratitis and keratic
More informationOral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children
Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children Daniel S. Choi, BA, and Ali Djalilian, MD Author affiliations: Department of
More informationAnti-allergic ophthalmic drugs in general practice: which, why and when?
Anti-allergic ophthalmic drugs in general practice: which, why and when? Abstract Mohamed N, MBChB, FC Ophth(SA), Registrar; Smit DP, MBChB, MMed(Ophth), FCOphth(SA), Consultant Division of Ophthalmology,
More informationRole of Th17 cells in the immunopathogenesis of dry eye disease
Role of Th17 cells in the immunopathogenesis of dry eye disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Chauhan,
More informationEfficacy of 0.05% Cyclosporine A Eye Drops in Allergic Conjunctivitis in terms of Improvement in Ocular Itching Score
ORIGINAL ARTICLE Efficacy of 0.05% Cyclosporine A Eye Drops in Allergic Conjunctivitis in terms of Improvement in Ocular Itching Score 1 2 3 Muhammad Saleh Faisal, Kashif Ur Rehman Khalil, Mian Asim Shah
More informationClinical evaluation criteria of ocular allergy by ophthalmologists in Kenya and suggested grading systems
Clinical evaluation criteria of ocular allergy by ophthalmologists in Kenya and suggested grading systems Bore M 1, Ilako DR 1, Kariuki MM 1, Nzinga JM 2 1 Department of Ophthamology, College of Health
More informationUncovering Contact Lens Discoveries. Joe Barr, OD, MS, FAAO. Key findings of Donald Korb, OD and the presenter s and colleague s work that he inspired
Uncovering Contact Lens Discoveries Joe Barr, OD, MS, FAAO Dr. Donald R. Korb Award for Excellence Lecture June 30, 2016 Key findings of Donald Korb, OD and the presenter s and colleague s work that he
More informationConjunctivitis in Dogs
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Conjunctivitis in Dogs (Inflammation of the Moist Tissues of the Eye) Basics OVERVIEW
More informationHuman high-affinity IgE receptor (Fc RI) exists in two isoform,
Hyperexpression of the High-Affinity IgE Receptor- Chain in Chronic Allergic Keratoconjunctivitis Akira Matsuda, 1 Yoshimichi Okayama, 2 Nobuyuki Ebihara, 3 Norihiko Yokoi, 1 Junji Hamuro, 1 Andrew F.
More informationPost-LASIK infections
Post-LASIK infections By Mohamed El-moddather Assiss. Prof. and head of department of ophthalmology AL-Azhar unizersity Assuit LASIK has become a common refractive procedure and is generally considered
More informationAllergic Conjunctivitis
Allergic Conjunctivitis ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Allergic conjunctivitis usually causes mild to moderate symptoms, including redness, which respond to non medicated treatment.
More informationkeratoconjunctivitis and the effect of treatment with sodium cromoglycate
British Journal of Ophthalmology, 1981, 65, 335-340 Clinical features and diagnosis of adult atopic keratoconjunctivitis and the effect of treatment with sodium cromoglycate JEFFREY L. JAY From the Tennant
More informationa.superficial (adenoid layer).contain lymphoid tissue.
Conjunctiva Dr. saifalshamarti Anatomy Microscopic: 1.Epithelium (non keratinized,includes goblet cell). 2.Epithelial basement membrane. 3.Stroma : a.superficial (adenoid layer).contain lymphoid tissue.
More informationThe allergic eye. Abstract. Introduction. Types of allergic conjunctivitis. Non-severe allergic conjunctivitis:
The allergic eye Andre Marais Senior lecturer and Clinical Pharmacologist Department of Pharmacology, School of Medicine, Faculty of Health Sciences, University of Pretoria, South Africa Correspondence
More informationConjunctivitis - Allergic, Seasonal & Perennial (1 of 6) Patient presents w/ symptoms suggestive of allergic conjunctivitis
, Seasonal & Perennial ( of 6) A B Patient presents w/ symptoms suggestive of allergic conjunctivitis Non-pharmacological therapy 2 DIAGNOSIS Does the clinical presentation confirm seasonal or perennial
More informationINDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.
Page 1 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) ACULAR 0,4% COMPOSITION ACULAR 0,4% ophthalmic solution contains: Ketorolac tromethamine: 4 mg/ml Preservative: Benzalkonium chloride
More informationCase no.4. Subjective. Subjective (2) Caucasian female, 62 Y.O., consulting for a XXX opinion on her condition.
Case no.4 Contact lenses: cause Subjective Caucasian female, 62 Y.O., consulting for a XXX opinion on her condition. Works as a lab technician for a veterenary surgeon No exposure to chemicals Had been
More informationD90 (27/10/2005) Final SmPC NL/H/653/01
1/6 1. NAME OF THE MEDICINAL PRODUCT MONOFREE DEXAMETHASON 1 mg/ml, eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains 1 mg of dexamethasone phosphate as dexamethasone
More informationRecommendations for Dietary Supplement Use for Dry Eye by Ophthalmologists in Japan and Their Personal Use: A Survey Report
Quality in Primary Care (2017) 25 (6): 372-378 2017 Insight Medical Publishing Group Review Article Research Article Recommendations for Dietary Supplement Use for Dry Eye by Ophthalmologists in Japan
More informationSkin Prick Test Reactivity to Aeroallergens among Egyptian Patients with Isolated Allergic Conjunctival Disease
THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 22 (2), 2015 Page: 41-47 Skin Prick Test Reactivity to Aeroallergens among Egyptian Patients with Isolated Allergic Conjunctival Disease 1 Fawzeia H. Abo-Ali, 1
More informationParacentral Corneal Melting in Four Patients With Chronic Graft-Versus-Host Disease
Paracentral Corneal Melting in Four Patients With Chronic Graft-Versus-Host Disease Neil Chungfat, MD, MEng 1,2 ; Jocelyn Rowe, MD 1,3 ; Neal P. Barney, MD 1 ; Sarah Nehls, MD 1 The authors have no financial
More informationTherapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease
Mun et al. BMC Ophthalmology (2018) 18:237 https://doi.org/10.1186/s12886-018-0910-3 RESEARCH ARTICLE Open Access Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film
More informationREAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE
REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE Tina H Chiang 1, John G Walt 1, John P McMahon, Jr. 2, James E Mansfield, Jr. 2, Susan Simonyi 3 1 Allergan
More informationCurrent Practice Pattern for Dry Eye Patients in South Korea: A Multicenter Study
pissn: 11-8942 eissn: 92-9382 Korean J Ophthalmol 14;28(2):115-121 http://dx.doi.org/.3341/kjo.14.28.2.115 Original Article Current Practice Pattern for Dry Eye Patients in South Korea: A Multicenter Study
More informationDoes in-office manual expression for Meibomian Gland Dysfunction (MGD) work?
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/282816021 Does in-office manual expression for Meibomian Gland Dysfunction (MGD) work? Conference
More informationAuthor's response to reviews
Author's response to reviews Title:Efficacy of 1% carboxymethylcellulose sodium for treating dry eye after phacoemulsification: results from a multicenter, open-label, randomized, controlled study Authors:
More informationTransplantation of Human Limbal Epithelium Cultivated on Amniotic Membrane for the Treatment of Severe Ocular Surface Disorders
Transplantation of Human Limbal Epithelium Cultivated on Amniotic Membrane for the Treatment of Severe Ocular Surface Disorders Jun Shimazaki, MD, Masayo Aiba, BS, Eiki Goto, MD, Naoko Kato, MD, Shigeto
More informationBill Kilgore, LDO,NCLE,COA Virginia Mason Medical Center
Bill Kilgore, LDO,NCLE,COA Virginia Mason Medical Center bkilgore@specialcontactfits.com NONE Five Primary Categories of Contact Lens Complications Eyelids Tear Film Conjunctiva/Limbus Cornea Other Hypoxia:
More informationCORNEAL CONDITIONS CORNEAL TRANSPLANTATION
GENERAL INFORMATION CORNEAL CONDITIONS CORNEAL TRANSPLANTATION WHAT ARE CORNEAL CONDITIONS? The cornea is the clear outer layer of the eye. Shaped like a dome, it helps to protect the eye from foreign
More informationWhat are some common conditions that affect the cornea?
What are some common conditions that affect the cornea? Injuries After minor injuries or scratches, the cornea usually heals on its own. Deeper injuries can cause corneal scarring, resulting in a haze
More informationGIVE THEM A DROP THAT LASTS Proven effective through 16 hours1-3
FOR PATIENTS WITH ITCHING DUE TO ALLERGIC CONJUNCTIVITIS INDICATIONS AND USAGE LASTACAFT (alcaftadine ophthalmic solution) 0.25% is an H1 histamine receptor antagonist indicated for the prevention of itching
More informationNEW OPPORTUNITIES OF USING THERAPEUTICAL CONTACT LENSES IN OCULAR SURGERY
NEW OPPORTUNITIES OF USING THERAPEUTICAL CONTACT LENSES IN OCULAR SURGERY Authors: Prof univ. dr. Adriana Stănilă, Dr. Elena Mihai, Dr. Adrian Teodoru, Dr. IonuŃ Costache The Clinical Department of Op
More informationSupplementary Online Content
Supplementary Online Content Uchino Y, Uchino M, Yokoi N, et al. Alteration of tear mucin 5AC in office workers using visual display terminals: the Osaka Study. JAMA Ophthalmol. Published online June 5,
More informationThe prevalence of dry eye (DE) disease has increased. Dry-Eye Screening by Using a Functional Visual Acuity Measurement System: The Osaka Study
Clinical and Epidemiologic Research Dry-Eye Screening by Using a Functional Visual Acuity Measurement System: The Osaka Study Minako Kaido, 1 Miki Uchino, 1,2 Norihiko Yokoi, 3 Yuichi Uchino, 1 Murat Dogru,
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dexafree 1 mg/ml, eye drops, solution in single-dose container 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml solution contains 1 mg
More informationEfficacy of Bromfenac Sodium Ophthalmic Solution for Treatment of Dry Eye Disease
ORIGINAL CLINICAL STUDY Efficacy of Bromfenac Sodium Ophthalmic Solution for Treatment of Dry Eye Disease Hiroshi Fujishima, MD,* Miki Fuseya, MD,Þ Masarou Ogata, MD,Þ and Dogru Murat, MD, PhDþ Purpose:
More informationDry Eye Prescribing Guidelines
Dry Eye Prescribing Guidelines Amendment History VERSION DATE AMENDMENT HISTORY V1.0 2011 Comments V1.1 2013 Updated V1.1 2017 Draft Updated Thealoz Duo replaces carmellose Optive in severe dry eye on
More informationNew Zealand Data Sheet
New Zealand Data Sheet Prednisolone-AFT 1% Prednisolone acetate (Ph Eur) 1% w/v ophthalmic suspension Presentation Prednisolone-AFT 1% is a milky white suspension in an eyedropper bottle for ophthalmic
More informationJMSCR Vol 07 Issue 04 Page April 2019
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i4.19 Original Research Article Use of Plasma Rich in Growth Factors
More informationAllergic Eye Disease: Pathophysiology, Clinical Manifestations and Treatment
Allergic Eye Disease: Pathophysiology, Clinical Manifestations and Treatment 14 Bita Manzouri, Thomas Flynn, Santa Jeremy Ono Core Messages Allergic eye disease affects a reported 20% of the population
More informationThe Effects of Systemic Medication on Ocular Allergic Disease
The Effects of Systemic Medication on Ocular Allergic Disease Gregg J. Berdy, MD, FACS Clinical Instructor in Ophthalmology, Washington University School of Medicine Key words: ocular allergic disease
More informationOverview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...
Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye... This Allergan sponsored session was held on July 24, 2005, Hotel Satya Ashoka, Jabalpur. The session was followed
More informationTrifluridine Ophthalmic Solution, 1% Sterile
Trifluridine Ophthalmic Solution, 1% Sterile DESCRIPTION Trifluridine (also known as trifluorothymidine, F 3 TdR,F 3 T), is an antiviral drug for topical treatment of epithelial keratitis caused by herpes
More informationDNB Question Paper. December
DNB Question Paper December PAPER - I 1. Discuss clinical features, pathogenesis and management of normal tension glaucoma. (3+3+4) 2. Describe clinical manifestations, pathology, differential diagnosis
More informationPostoperative follow up and treatment after refractive surgery
Postoperative follow up and treatment after refractive surgery George Kontadakis, MD, MSc, PhD Institute of Vision and Optics and Department of Ophthalmology University of Crete Target of postoperative
More informationTherapeutical bandage contact lenses for corneal protection
Therapeutical bandage contact lenses for corneal protection M i c h a e l B a e r t s c h i M.S.Optom Optom., M.Med.Educ Educ.,., F.A.A.O. Contact for text manuscript demands michael.baertschi baertschi@bluewin.ch
More informationYukihisa Takada, Yuka Okada, Norihito Fujita, and Shizuya Saika. 1. Introduction. 2. Case Presentation
Case Reports in Ophthalmological Medicine Volume 2012, Article ID 536746, 4 pages doi:10.1155/2012/536746 Case Report A Patient with Corneal Epithelial Disorder That Developed after Administration of a
More information